Get the Stockscreener App
58.88
0.79%
-0.47
After Hours:
58.88
Xenon Pharmaceuticals Inc stock is traded at $58.88, with a volume of 937.43K.
It is down -0.79% in the last 24 hours and up +6.61% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$59.35
Open:
$59.7
24h Volume:
937.43K
Relative Volume:
0.70
Market Cap:
$5.62B
Revenue:
$7.50M
Net Income/Loss:
$-345.91M
P/E Ratio:
-13.50
EPS:
-4.3602
Net Cash Flow:
$-280.51M
1W Performance:
+2.33%
1M Performance:
+6.61%
6M Performance:
+40.53%
1Y Performance:
+78.26%
1-Day Range:
$58.35
$59.70
1-Week Range:
$57.44
$59.99
52-Week Range:
$28.19
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
58.88 | 5.66B | 7.50M | -345.91M | -280.51M | -4.3602 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon to Present at Upcoming Investor Conferences - Toronto Star
Xenon Expands 2025 Inducement Equity Incentive Plan - The Globe and Mail
Xenon Pharmaceuticals Amends 2025 Inducement Equity Incentive Plan for Nasdaq Compliance and Employee Attraction 10 - Minichart
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan
Certain Restricted Stock Units of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Stock Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Published on: 2026-04-09 12:46:57 - baoquankhu1.vn
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN By Investing.com - Investing.com Australia
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting - Bitget
Xenon brings 48-month epilepsy drug data and Phase 3 results to AAN - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - AOL.com
XENE SEC FilingsXenon Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) climbs 31.7% as epilepsy treatment moves forward - MSN
XENE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
XENE PE Ratio & Valuation, Is XENE Overvalued - Intellectia AI
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
XENE Should I Buy - Intellectia AI
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals stock soars 20% in 3 months: Here's why - MSN
How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors - Sahm
Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 Results And US$750 Million Capital Raise - Sahm
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool
Xenon Pharmaceuticals (XENE) price target increased by 41.64% to 80.01 - MSN
Wolfe Research initiates coverage of Xenon Pharmaceuticals (XENE) with outperform recommendation - MSN
Crude oil rises around 4%; Xenon Pharmaceuticals shares surge - MSN
(XENE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Published on: 2026-03-22 04:08:37 - baoquankhu1.vn
Xenon Pharmaceuticals rallies after pivotal data shows major drop in monthly seizures - MSN
Xenon Pharmaceuticals stock faces pipeline scrutiny amid biotech sector volatility - AD HOC NEWS
JPMorgan Chase & Co. Purchases 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com
Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained - Bitget
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - The Globe and Mail
Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):